United States - English - NLM (National Library of Medicine)

jacobus pharmaceutical company, inc. - aminosalicylic acid (unii: 5b2658e0n2) (aminosalicylic acid - unii:5b2658e0n2) - aminosalicylic acid 4 g - paser is indicated for the treatment of tuberculosis in combination with other active agents. it is most commonly used in patients with multi-drug resistant tb (mdr-tb) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. when paser is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible. hypersensitivity to any component of this medication. severe renal disease. patients with severe renal disease will accumulate aminosalicylic acid and its acetyl metabolite but will continue to acetylate, thus leading exclusively to the inactive acetylated form; deacetylation, if any, is not significant. the half life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison to 26.4 minutes in normal volunteers. but the half life of the inactive metabolite is 30

European Union - English - EMA (European Medicines Agency)

eurocept international b. v. - para-aminosalicylic acid - tuberculosis - antimycobacterials - granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

fagron inc - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) -

Israel - English - Ministry of Health

truemed ltd, israel - 4 - aminosalicylic acid - gastro resistant granules - 4 - aminosalicylic acid 4 g/sachet - 4-aminosalicylic acid - granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Canada - English - Health Canada

teva canada limited - mesalazine - tablet (enteric-coated) - 400mg - mesalazine 400mg - anti-inflammatory agents

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine (5 - aminosalicylic acid) - granules prolonged release gastro resistant - mesalazine (5 - aminosalicylic acid) 1 g - mesalazine - for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine (5 - aminosalicylic acid) - granules prolonged release gastro resistant - mesalazine (5 - aminosalicylic acid) 1 g - mesalazine - for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine (5 - aminosalicylic acid) - granules prolonged release gastro resistant - mesalazine (5 - aminosalicylic acid) 1.5 g - mesalazine - for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine (5 - aminosalicylic acid) - granules prolonged release gastro resistant - mesalazine (5 - aminosalicylic acid) 1.5 g - mesalazine - for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine (5 - aminosalicylic acid) - granules prolonged release gastro resistant - mesalazine (5 - aminosalicylic acid) 3 g - mesalazine - for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.